CIK免疫治疗联合TP方案化疗对食管癌生存质量的影响  

Effects of CIK Immunotherapy Combined with Nedaplatin+Paclitaxel Chemotherapy on Quality of Life in Esophageal Cancer

作　　者：王孟蝶 祁宁宁 侯园 WANG Mengdie;QI Ningning;HOU Yuan(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000 China)

机构地区：[1]河南科技大学第一附属医院,河南洛阳471000

出　　处：《锦州医科大学学报》2025年第1期87-91,共5页Journal of Jinzhou Medical University

基　　金：2020年度河南省医学科技攻关计划省部共建项目,项目编号:SBGJ202002100。

摘　　要：目的观察细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)免疫治疗联合奈达铂+紫杉醇方案化疗对食管癌患者临床疗效及生存质量的影响。方法选取河南科技大学第一附属医院收治的66例食管癌患者,病例纳入时间为2020年1月至2022年1月,随机均分为研究组(n=33)和对照组(n=33)。对照组给予奈达铂+紫杉醇方案化疗,在此基础上研究组加用CIK免疫治疗。比较两组临床疗效、治疗前后免疫指标、生存质量、毒副反应及随访24个月的生存情况。结果研究组客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)高于对照组(P<0.05);治疗后,研究组血清T淋巴细胞亚群CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)比值水平高于对照组(P<0.05);研究组卡氏功能状态(KPS)评分高于对照组(P<0.05);治疗期间,研究组骨髓抑制和肝肾功能损害的毒副反应总发生率低于对照组(P<0.05);随访结果,研究组12个月和24个月的生存率高于对照组(P<0.05)。结论CIK免疫治疗联合奈达铂+紫杉醇方案化疗可有效提高食管癌患者的临床疗效,改善机体免疫功能,提高生存质量,降低毒副反应,并一定程度上延长生存期。Objective To observe the influences of cytokine induced killer(CIK)immunotherapy combined with nedaplatin+paclitaxel chemotherapy on clinical curative effect and quality of life in patients with esophageal cancer.Methods 66 patients with esophageal cancer admitted to our hospital were selected from January 2020 to January 2022,and were randomly divided into study group(n=33)and control group(n=33).The control group was given nedaplatin+paclitaxel chemotherapy,while the study group was additionally given CIK immunotherapy.The clinical curative effect,immune indexes,quality of life and toxicity before and after treatment,and survival within 24 months of follow-up in the two groups were compared.Results The objective response rate(ORR)and disease control rate(DCR)in study group were higher than those in control group(P<0.05).After treatment,levels of serum T lymphocyte subsets CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in study group were higher than those in control group(P<0.05).The score of Karnofsky performance status(KPS)in study group was higher than that in control group(P<0.05).During treatment,total incidence of toxicity(myelosuppression,liver-kidney function impairment)in study group was lower than that in control group(P<0.05).The follow-up results showed that 12-month and 24-month survival rates in study group were higher than those in control group(P<0.05).Conclusion CIK immunotherapy combined with nedaplatin+paclitaxel chemotherapy can effectively improve clinical curative effect,immune function and quality of life in patients with esophageal cancer,reduce toxicity and prolong survival time to certain extent.

关 键 词：细胞因子诱导的杀伤细胞 细胞免疫 奈达铂 紫杉醇 食管癌 生存质量 

分 类 号：R735.1[医药卫生—肿瘤]